Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder
Identifieur interne : 001053 ( Istex/Corpus ); précédent : 001052; suivant : 001054Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder
Auteurs : Hun Soo Chang ; Hwa-Young Lee ; Byung-Joo Ham ; Yong Chon Park ; Sang-Woo Hahn ; Yoo-Jung Jeong ; Bohye Kim ; Min-Soo LeeSource :
- Asia‐Pacific Psychiatry [ 1758-5864 ] ; 2012-12.
Abstract
Brain‐derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD).
Url:
DOI: 10.1111/j.1758-5872.2012.00219.x
Links to Exploration step
ISTEX:7B825E43DB430BE8729B3832C34CC2FECE0B7E91Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title><author><name sortKey="Chang, Hun Soo" sort="Chang, Hun Soo" uniqKey="Chang H" first="Hun Soo" last="Chang">Hun Soo Chang</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Hwa Oung" sort="Lee, Hwa Oung" uniqKey="Lee H" first="Hwa-Young" last="Lee">Hwa-Young Lee</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Ham, Byung Oo" sort="Ham, Byung Oo" uniqKey="Ham B" first="Byung-Joo" last="Ham">Byung-Joo Ham</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Park, Yong Chon" sort="Park, Yong Chon" uniqKey="Park Y" first="Yong Chon" last="Park">Yong Chon Park</name><affiliation><mods:affiliation>Department of Neuropsychiatry, College of Medicine, Hanyang University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Hahn, Sang Oo" sort="Hahn, Sang Oo" uniqKey="Hahn S" first="Sang-Woo" last="Hahn">Sang-Woo Hahn</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Jeong, Yoo Ung" sort="Jeong, Yoo Ung" uniqKey="Jeong Y" first="Yoo-Jung" last="Jeong">Yoo-Jung Jeong</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Bohye" sort="Kim, Bohye" uniqKey="Kim B" first="Bohye" last="Kim">Bohye Kim</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Min Oo" sort="Lee, Min Oo" uniqKey="Lee M" first="Min-Soo" last="Lee">Min-Soo Lee</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐gu, Seoul 136‐705, Korea.Tel: +82 2 920 5354Fax: +82 2 923 3507, ext. 5998Email:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: leeminso@korea.ac.kr</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7B825E43DB430BE8729B3832C34CC2FECE0B7E91</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1758-5872.2012.00219.x</idno><idno type="url">https://api.istex.fr/document/7B825E43DB430BE8729B3832C34CC2FECE0B7E91/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001053</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001053</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title><author><name sortKey="Chang, Hun Soo" sort="Chang, Hun Soo" uniqKey="Chang H" first="Hun Soo" last="Chang">Hun Soo Chang</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Hwa Oung" sort="Lee, Hwa Oung" uniqKey="Lee H" first="Hwa-Young" last="Lee">Hwa-Young Lee</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Ham, Byung Oo" sort="Ham, Byung Oo" uniqKey="Ham B" first="Byung-Joo" last="Ham">Byung-Joo Ham</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Park, Yong Chon" sort="Park, Yong Chon" uniqKey="Park Y" first="Yong Chon" last="Park">Yong Chon Park</name><affiliation><mods:affiliation>Department of Neuropsychiatry, College of Medicine, Hanyang University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Hahn, Sang Oo" sort="Hahn, Sang Oo" uniqKey="Hahn S" first="Sang-Woo" last="Hahn">Sang-Woo Hahn</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Jeong, Yoo Ung" sort="Jeong, Yoo Ung" uniqKey="Jeong Y" first="Yoo-Jung" last="Jeong">Yoo-Jung Jeong</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Bohye" sort="Kim, Bohye" uniqKey="Kim B" first="Bohye" last="Kim">Bohye Kim</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Min Oo" sort="Lee, Min Oo" uniqKey="Lee M" first="Min-Soo" last="Lee">Min-Soo Lee</name><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐gu, Seoul 136‐705, Korea.Tel: +82 2 920 5354Fax: +82 2 923 3507, ext. 5998Email:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: leeminso@korea.ac.kr</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Asia‐Pacific Psychiatry</title><title level="j" type="abbrev">Asia‐Pacific Psychiatry</title><idno type="ISSN">1758-5864</idno><idno type="eISSN">1758-5872</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2012-12">2012-12</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="241">241</biblScope><biblScope unit="page" to="249">249</biblScope></imprint><idno type="ISSN">1758-5864</idno></series><idno type="istex">7B825E43DB430BE8729B3832C34CC2FECE0B7E91</idno><idno type="DOI">10.1111/j.1758-5872.2012.00219.x</idno><idno type="ArticleID">APPY219</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1758-5864</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Brain‐derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD).</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Hun Soo Chang MD PhD</name><affiliations><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Hwa‐Young Lee MD PhD</name><affiliations><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Byung‐Joo Ham MD PhD</name><affiliations><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yong Chon Park MD PhD</name><affiliations><json:string>Department of Neuropsychiatry, College of Medicine, Hanyang University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Sang‐Woo Hahn MD PhD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yoo‐Jung Jeong MS</name><affiliations><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Bohye Kim MS</name><affiliations><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Min‐Soo Lee MD PhD</name><affiliations><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐gu, Seoul 136‐705, Korea.Tel: +82 2 920 5354Fax: +82 2 923 3507, ext. 5998Email:</json:string><json:string>E-mail: leeminso@korea.ac.kr</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>brain‐derived neurotrophic factor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>escitalopram</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>major depressive disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>single nucleotide polymorphism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment response</value></json:item></subject><articleId><json:string>APPY219</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>5.822</score><pdfVersion>1.4</pdfVersion><pdfPageSize>595.276 x 779.528 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>432</abstractCharCount><pdfWordCount>4590</pdfWordCount><pdfCharCount>31241</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>61</abstractWordCount></qualityIndicators><title>Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title><refBibs><json:item><author><json:item><name>S. Alboni</name></json:item><json:item><name>C. Benatti</name></json:item><json:item><name>G. Capone</name></json:item></author><host><volume>643</volume><pages><last>187</last><first>180</first></pages><issue>2–3</issue><author></author><title>Eur J Pharmacol</title></host><title>Time‐dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats</title></json:item><json:item><author><json:item><name>C.A. Altar</name></json:item></author><host><volume>20</volume><pages><last>61</last><first>59</first></pages><issue>2</issue><author></author><title>Trends Pharmacol Sci</title></host><title>Neurotrophins and depression</title></json:item><json:item><author><json:item><name>S. Aronson</name></json:item><json:item><name>P. Delgado</name></json:item></author><host><volume>40</volume><pages><last>131</last><first>121</first></pages><issue>2</issue><author></author><title>Drugs Today (Barc)</title></host><title>Escitalopram</title></json:item><json:item><author><json:item><name>H.H. Berendsen</name></json:item><json:item><name>C.L. Broekkamp</name></json:item></author><host><volume>133</volume><pages><last>282</last><first>275</first></pages><issue>3</issue><author></author><title>Psychopharmacology (Berl)</title></host><title>Indirect in vivo 5‐HT1A‐agonistic effects of the new antidepressant mirtazapine</title></json:item><json:item><author><json:item><name>T. de Boer</name></json:item></author><host><volume>57</volume><pages><last>25</last><first>19</first></pages><issue>Suppl 4</issue><author></author><title>J Clin Psychiatry</title></host><title>The pharmacologic profile of mirtazapine</title></json:item><json:item><host><author></author><title>Buchner A., Faul F., Erdfelder E. (1996) G•Power: A Priori, Post‐Hoc, and Compromise Power Analyses for the Macintosh (Version 2.1.1). University of Trier, Trier.</title></host></json:item><json:item><author><json:item><name>A. Cattaneo</name></json:item><json:item><name>L. Bocchio‐Chiavetto</name></json:item><json:item><name>R. Zanardini</name></json:item><json:item><name>E. Milanesi</name></json:item><json:item><name>A. Placentino</name></json:item><json:item><name>M. Gennarelli</name></json:item></author><host><volume>13</volume><pages><last>108</last><first>103</first></pages><issue>1</issue><author></author><title>Int J Neuropsychopharmacol</title></host><title>Reduced peripheral brain‐derived neurotrophic factor mRNA levels are normalized by antidepressant treatment</title></json:item><json:item><author><json:item><name>D.S. Charney</name></json:item></author><host><volume>59</volume><pages><last>14</last><first>11</first></pages><issue>Suppl 14</issue><author></author><title>J Clin Psychiatry</title></host><title>Monoamine dysfunction and the pathophysiology and treatment of depression</title></json:item><json:item><author><json:item><name>B. Chen</name></json:item><json:item><name>D. Dowlatshahi</name></json:item><json:item><name>G.M. MacQueen</name></json:item><json:item><name>J.F. Wang</name></json:item><json:item><name>L.T. Young</name></json:item></author><host><volume>50</volume><pages><last>265</last><first>260</first></pages><issue>4</issue><author></author><title>Biol Psychiatry</title></host><title>Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication</title></json:item><json:item><author><json:item><name>F. Chen</name></json:item><json:item><name>M.B. Larsen</name></json:item><json:item><name>C. Sánchez</name></json:item><json:item><name>O. Wiborg</name></json:item></author><host><volume>15</volume><pages><last>198</last><first>193</first></pages><issue>2</issue><author></author><title>Eur Neuropsychopharmacol</title></host><title>The S‐enantiomer of R,S‐citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors</title></json:item><json:item><author><json:item><name>M.J. Choi</name></json:item><json:item><name>R.H. Kang</name></json:item><json:item><name>S.W. Lim</name></json:item><json:item><name>K.S. Oh</name></json:item><json:item><name>M.S. Lee</name></json:item></author><host><volume>1118</volume><pages><last>182</last><first>176</first></pages><issue>1</issue><author></author><title>Brain Res</title></host><title>Brain‐derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder</title></json:item><json:item><author><json:item><name>J.T. Coyle</name></json:item><json:item><name>R.S. Duman</name></json:item></author><host><volume>38</volume><pages><last>160</last><first>157</first></pages><issue>2</issue><author></author><title>Neuron</title></host><title>Finding the intracellular signaling pathways affected by mood disorder treatments</title></json:item><json:item><author><json:item><name>P.L. Delgado</name></json:item><json:item><name>F.A. Moreno</name></json:item></author><host><volume>61</volume><pages><last>12</last><first>5</first></pages><issue>Suppl 1</issue><author></author><title>J Clin Psychiatry</title></host><title>Role of norepinephrine in depression</title></json:item><json:item><author><json:item><name>K. Domschke</name></json:item><json:item><name>B. Lawford</name></json:item><json:item><name>G. Laje</name></json:item></author><host><volume>13</volume><pages><last>101</last><first>93</first></pages><issue>1</issue><author></author><title>Int J Neuropsychopharmacol</title></host><title>Brain‐derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response</title></json:item><json:item><author><json:item><name>R.S. Duman</name></json:item></author><host><volume>7</volume><pages><last>34</last><first>29</first></pages><issue>Suppl 1</issue><author></author><title>Mol Psychiatry</title></host><title>Synaptic plasticity and mood disorders</title></json:item><json:item><author><json:item><name>R.S. Duman</name></json:item><json:item><name>D.S. Charney</name></json:item></author><host><volume>45</volume><pages><last>1084</last><first>1083</first></pages><issue>9</issue><author></author><title>Biol Psychiatry</title></host><title>Cell atrophy and loss in major depression</title></json:item><json:item><author><json:item><name>R.S. Duman</name></json:item><json:item><name>G.R. Heninger</name></json:item><json:item><name>E.J. Nestler</name></json:item></author><host><volume>54</volume><pages><last>606</last><first>597</first></pages><issue>7</issue><author></author><title>Arch Gen Psychiatry</title></host><title>A molecular and cellular theory of depression</title></json:item><json:item><author><json:item><name>J. Fawcett</name></json:item><json:item><name>R.L. Barkin</name></json:item></author><host><volume>51</volume><pages><last>285</last><first>267</first></pages><issue>3</issue><author></author><title>J Affect Disord</title></host><title>Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression</title></json:item><json:item><author><json:item><name>E. Frank</name></json:item><json:item><name>R.F. Prien</name></json:item><json:item><name>R.B. Jarrett</name></json:item></author><host><volume>48</volume><pages><last>855</last><first>851</first></pages><issue>9</issue><author></author><title>Arch Gen Psychiatry</title></host><title>Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence</title></json:item><json:item><author><json:item><name>N. Gervasoni</name></json:item><json:item><name>J.M. Aubry</name></json:item><json:item><name>G. Bondolfi</name></json:item></author><host><volume>51</volume><pages><last>238</last><first>234</first></pages><issue>4</issue><author></author><title>Neuropsychobiology</title></host><title>Partial normalization of serum brain‐derived neurotrophic factor in remitted patients after a major depressive episode</title></json:item><json:item><author><json:item><name>J.M. Gorman</name></json:item><json:item><name>A. Korotzer</name></json:item><json:item><name>G. Su</name></json:item></author><host><volume>7</volume><pages><last>44</last><first>40</first></pages><issue>4 Suppl 1</issue><author></author><title>CNS Spectr</title></host><title>Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo‐controlled trials</title></json:item><json:item><author><json:item><name>P. Gorwood</name></json:item></author><host><pages><last>121</last><first>113</first></pages><author></author><title>Handbook of Molecular‐genetic Techniques for Brain and Behavior Research</title></host><title>Genetic association studies in behavioral neuroscience</title></json:item><json:item><author><json:item><name>T.L. Huang</name></json:item><json:item><name>C.T. Lee</name></json:item><json:item><name>Y.L. Liu</name></json:item></author><host><volume>42</volume><pages><last>525</last><first>521</first></pages><issue>7</issue><author></author><title>J Psychiatr Res</title></host><title>Serum brain‐derived neurotrophic factor levels in patients with major depression: effects of antidepressants</title></json:item><json:item><author><json:item><name>K.R. Jones</name></json:item><json:item><name>L.F. Reichardt</name></json:item></author><host><volume>87</volume><pages><last>8064</last><first>8060</first></pages><issue>20</issue><author></author><title>Proc Natl Acad Sci USA</title></host><title>Molecular cloning of a human gene that is a member of the nerve growth factor family</title></json:item><json:item><author><json:item><name>R. Kang</name></json:item><json:item><name>H. Chang</name></json:item><json:item><name>M. Wong</name></json:item></author><host><volume>24</volume><pages><last>1763</last><first>1755</first></pages><issue>12</issue><author></author><title>J Psychopharmacol</title></host><title>Brain‐derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression</title></json:item><json:item><host><author></author><title>Kim J.W. (2003) Association Study and the Population Admixture. Human Neurobehavioral Genetics in the 21st Century. Korean Society of Biological Psychiatry, Seoul.</title></host></json:item><json:item><author><json:item><name>J. Leibrock</name></json:item><json:item><name>F. Lottspeich</name></json:item><json:item><name>A. Hohn</name></json:item></author><host><volume>341</volume><pages><last>152</last><first>149</first></pages><issue>6238</issue><author></author><title>Nature</title></host><title>Molecular cloning and expression of brain‐derived neurotrophic factor</title></json:item><json:item><author><json:item><name>L.A. Mamounas</name></json:item><json:item><name>M.E. Blue</name></json:item><json:item><name>J.A. Siuciak</name></json:item><json:item><name>C.A. Altar</name></json:item></author><host><volume>15</volume><pages><last>7939</last><first>7929</first></pages><issue>12</issue><author></author><title>J Neurosci</title></host><title>Brain‐derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain</title></json:item><json:item><author><json:item><name>M.E. Mansari</name></json:item><json:item><name>O. Wiborg</name></json:item><json:item><name>O. Mnie‐Filali</name></json:item><json:item><name>N. Benturquia</name></json:item><json:item><name>C. Sánchez</name></json:item><json:item><name>N. Haddjeri</name></json:item></author><host><volume>10</volume><pages><last>40</last><first>31</first></pages><issue>1</issue><author></author><title>Int J Neuropsychopharmacol</title></host><title>Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in‐vitro and in‐vivo studies</title></json:item><json:item><author><json:item><name>N. Moore</name></json:item><json:item><name>H. Verdoux</name></json:item><json:item><name>B. Fantino</name></json:item></author><host><volume>20</volume><pages><last>137</last><first>131</first></pages><issue>3</issue><author></author><title>Int Clin Psychopharmacol</title></host><title>Prospective, multicentre, randomized, double‐blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder</title></json:item><json:item><author><json:item><name>A. Mørk</name></json:item><json:item><name>M. Kreilgaard</name></json:item><json:item><name>C. Sánchez</name></json:item></author><host><volume>45</volume><pages><last>173</last><first>167</first></pages><author></author><title>Neuropharmacology</title></host><title>The R‐enantiomer of citalopram counteracts escitalopram‐induced increase in extracellular 5‐HT in the frontal cortex of freely moving rats</title></json:item><json:item><author><json:item><name>R. Mössner</name></json:item><json:item><name>S. Daniel</name></json:item><json:item><name>D. Albert</name></json:item></author><host><volume>36</volume><pages><last>202</last><first>197</first></pages><issue>3</issue><author></author><title>Neurochem Int</title></host><title>Serotonin transporter function is modulated by brain‐derived neurotrophic factor (BDNF) but not nerve growth factor (NGF)</title></json:item><json:item><author><json:item><name>S.J. Mowla</name></json:item><json:item><name>H.F. Farhadi</name></json:item><json:item><name>S. Pareek</name></json:item></author><host><volume>276</volume><pages><last>12666</last><first>12660</first></pages><issue>16</issue><author></author><title>J Biol Chem</title></host><title>Biosynthesis and post‐translational processing of the precursor to brain‐derived neurotrophic factor</title></json:item><json:item><author><json:item><name>E.J. Nestler</name></json:item><json:item><name>M. Barrot</name></json:item><json:item><name>R.J. DiLeone</name></json:item><json:item><name>A.J. Eisch</name></json:item><json:item><name>S.J. Gold</name></json:item><json:item><name>L.M. Monteggia</name></json:item></author><host><volume>34</volume><pages><last>25</last><first>13</first></pages><issue>1</issue><author></author><title>Neuron</title></host><title>Neurobiology of depression</title></json:item><json:item><author><json:item><name>E.J. Nestler</name></json:item><json:item><name>E. Gould</name></json:item><json:item><name>H. Manji</name></json:item></author><host><volume>52</volume><pages><last>528</last><first>503</first></pages><issue>6</issue><author></author><title>Biol Psychiatry</title></host><title>Preclinical models: status of basic research in depression</title></json:item><json:item><author><json:item><name>M.J. Owens</name></json:item><json:item><name>C.B. Nemeroff</name></json:item></author><host><volume>40</volume><pages><last>295</last><first>288</first></pages><issue>2</issue><author></author><title>Clin Chem</title></host><title>Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter</title></json:item><json:item><author><json:item><name>M. Pröschel</name></json:item><json:item><name>A. Saunders</name></json:item><json:item><name>A.D. Roses</name></json:item><json:item><name>C.R. Müller</name></json:item></author><host><volume>1</volume><pages><first>353</first></pages><issue>5</issue><author></author><title>Hum Mol Genet</title></host><title>Dinucleotide repeat polymorphism at the human gene for the brain‐derived neurotrophic factor (BDNF)</title></json:item><json:item><author><json:item><name>G. Rajkowska</name></json:item><json:item><name>J.J. Miguel‐Hidalgo</name></json:item><json:item><name>J. Wei</name></json:item></author><host><volume>45</volume><pages><last>1098</last><first>1085</first></pages><issue>9</issue><author></author><title>Biol Psychiatry</title></host><title>Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression</title></json:item><json:item><author><json:item><name>C. Sánchez</name></json:item><json:item><name>K.P. Bøgesø</name></json:item><json:item><name>B. Ebert</name></json:item><json:item><name>E.H. Reines</name></json:item><json:item><name>C. Braestrup</name></json:item></author><host><volume>174</volume><pages><last>176</last><first>163</first></pages><issue>2</issue><author></author><title>Psychopharmacology (Berl)</title></host><title>Escitalopram versus citalopram: the surprising role of the R‐enantiomer</title></json:item><json:item><author><json:item><name>O. Schulte‐Herbrüggen</name></json:item><json:item><name>E. Fuchs</name></json:item><json:item><name>N. Abumaria</name></json:item></author><host><volume>87</volume><pages><last>2560</last><first>2551</first></pages><issue>11</issue><author></author><title>J Neurosci Res</title></host><title>Effects of escitalopram on the regulation of brain‐derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress</title></json:item><json:item><author><json:item><name>Y.I. Sheline</name></json:item><json:item><name>M.H. Gado</name></json:item><json:item><name>H.C. Kraemer</name></json:item></author><host><volume>160</volume><pages><last>1518</last><first>1516</first></pages><issue>8</issue><author></author><title>Am J Psychiatry</title></host><title>Untreated depression and hippocampal volume loss</title></json:item><json:item><author><json:item><name>E. Shimizu</name></json:item><json:item><name>K. Hashimoto</name></json:item><json:item><name>N. Okamura</name></json:item></author><host><volume>54</volume><pages><last>75</last><first>70</first></pages><issue>1</issue><author></author><title>Biol Psychiatry</title></host><title>Alterations of serum levels of brain‐derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants</title></json:item><json:item><author><json:item><name>J.A. Siuciak</name></json:item><json:item><name>C.A. Altar</name></json:item><json:item><name>S.J. Wiegand</name></json:item><json:item><name>R.M. Lindsay</name></json:item></author><host><volume>633</volume><pages><last>330</last><first>326</first></pages><issue>1‐2</issue><author></author><title>Brain Res</title></host><title>Antinociceptive effect of brain‐derived neurotrophic factor and neurotrophin‐3</title></json:item><json:item><author><json:item><name>W.D. Taylor</name></json:item><json:item><name>D.R. McQuoid</name></json:item><json:item><name>A. Ashley‐Koch</name></json:item></author><host><volume>11</volume><pages><last>154</last><first>146</first></pages><issue>2</issue><author></author><title>Pharmacogenomics J</title></host><title>BDNF Val66Met genotype and 6‐month remission rates in late‐life depression</title></json:item><json:item><author><json:item><name>S.J. Tsai</name></json:item><json:item><name>C.Y. Cheng</name></json:item><json:item><name>Y.W. Yu</name></json:item><json:item><name>T.J. Chen</name></json:item><json:item><name>C.J. Hong</name></json:item></author><host><volume>123B</volume><pages><last>22</last><first>19</first></pages><issue>1</issue><author></author><title>Am J Med Genet B Neuropsychiatr Genet</title></host><title>Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response</title></json:item><json:item><author><json:item><name>S.J. Tsai</name></json:item><json:item><name>C.J. Hong</name></json:item><json:item><name>Y.W. Yu</name></json:item><json:item><name>T.J. Chen</name></json:item></author><host><volume>49</volume><pages><last>16</last><first>13</first></pages><issue>1</issue><author></author><title>Neuropsychobiology</title></host><title>Association study of a brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism and personality trait and intelligence in healthy young females</title></json:item><json:item><author><json:item><name>V.A. Vaidya</name></json:item><json:item><name>G.J. Marek</name></json:item><json:item><name>G.K. Aghajanian</name></json:item><json:item><name>R.S. Duman</name></json:item></author><host><volume>17</volume><pages><last>2795</last><first>2785</first></pages><issue>8</issue><author></author><title>J Neurosci</title></host><title>5‐HT2A receptor‐mediated regulation of brain‐derived neurotrophic factor mRNA in the hippocampus and the neocortex</title></json:item><json:item><author><json:item><name>R. Ventimiglia</name></json:item><json:item><name>P.E. Mather</name></json:item><json:item><name>B.E. Jones</name></json:item><json:item><name>R.M. Lindsay</name></json:item></author><host><volume>7</volume><pages><last>222</last><first>213</first></pages><issue>2</issue><author></author><title>Eur J Neurosci</title></host><title>The neurotrophins BDNF, NT‐3 and NT‐4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro</title></json:item><json:item><author><json:item><name>J.L. Warner‐Schmidt</name></json:item><json:item><name>R.S. Duman</name></json:item></author><host><volume>16</volume><pages><last>249</last><first>239</first></pages><issue>3</issue><author></author><title>Hippocampus</title></host><title>Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment</title></json:item><json:item><author><json:item><name>K. Yoshida</name></json:item><json:item><name>H. Higuchi</name></json:item><json:item><name>M. Kamata</name></json:item></author><host><volume>21</volume><pages><last>656</last><first>650</first></pages><issue>6</issue><author></author><title>J Psychopharmacol</title></host><title>The G196A polymorphism of the brain‐derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine</title></json:item><json:item><author><json:item><name>T.S. Zetterström</name></json:item><json:item><name>Q. Pei</name></json:item><json:item><name>T.R. Madhav</name></json:item><json:item><name>A.L. Coppell</name></json:item><json:item><name>L. Lewis</name></json:item><json:item><name>D.G. Grahame‐Smith</name></json:item></author><host><volume>38</volume><pages><last>1073</last><first>1063</first></pages><issue>7</issue><author></author><title>Neuropharmacology</title></host><title>Manipulations of brain 5‐HT levels affect gene expression for BDNF in rat brain</title></json:item><json:item><author><json:item><name>Y.F. Zou</name></json:item><json:item><name>Y. Wang</name></json:item><json:item><name>P. Liu</name></json:item></author><host><volume>61</volume><pages><last>78</last><first>71</first></pages><issue>2</issue><author></author><title>Neuropsychobiology</title></host><title>Association of brain‐derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>4</volume><publisherId><json:string>APPY</json:string></publisherId><pages><total>9</total><last>249</last><first>241</first></pages><issn><json:string>1758-5864</json:string></issn><issue>4</issue><subject><json:item><value>ORIGINAL ARTICLE</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1758-5872</json:string></eissn><title>Asia‐Pacific Psychiatry</title><doi><json:string>10.1111/(ISSN)1758-5872</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>psychiatry</json:string></wos><scienceMetrix></scienceMetrix></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1111/j.1758-5872.2012.00219.x</json:string></doi><id>7B825E43DB430BE8729B3832C34CC2FECE0B7E91</id><score>0.028139915</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/7B825E43DB430BE8729B3832C34CC2FECE0B7E91/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/7B825E43DB430BE8729B3832C34CC2FECE0B7E91/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7B825E43DB430BE8729B3832C34CC2FECE0B7E91/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><availability><p>© 2012 Wiley Publishing Asia Pty LtdCopyright © 2012 Blackwell Publishing Asia Pty Ltd</p></availability><date>2012-07-16</date></publicationStmt><notesStmt><note>Korea Health 21 R&D project</note><note>Ministry of Health and Welfare, Republic of Korea - No. A030001;</note><note>H. Lundbeck A/S</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title><author xml:id="author-1"><persName><forename type="first">Hun Soo</forename><surname>Chang</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-2"><persName><forename type="first">Hwa‐Young</forename><surname>Lee</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-3"><persName><forename type="first">Byung‐Joo</forename><surname>Ham</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-4"><persName><forename type="first">Yong Chon</forename><surname>Park</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>Department of Neuropsychiatry, College of Medicine, Hanyang University, Seoul, Korea</affiliation></author><author xml:id="author-5"><persName><forename type="first">Sang‐Woo</forename><surname>Hahn</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</affiliation></author><author xml:id="author-6"><persName><forename type="first">Yoo‐Jung</forename><surname>Jeong</surname></persName><roleName type="degree">MS</roleName><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-7"><persName><forename type="first">Bohye</forename><surname>Kim</surname></persName><roleName type="degree">MS</roleName><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-8"><persName><forename type="first">Min‐Soo</forename><surname>Lee</surname></persName><roleName type="degree">MD PhD</roleName><email>leeminso@korea.ac.kr</email><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐gu, Seoul 136‐705, Korea.Tel: +82 2 920 5354Fax: +82 2 923 3507, ext. 5998Email:</affiliation></author></analytic><monogr><title level="j">Asia‐Pacific Psychiatry</title><title level="j" type="abbrev">Asia‐Pacific Psychiatry</title><idno type="pISSN">1758-5864</idno><idno type="eISSN">1758-5872</idno><idno type="DOI">10.1111/(ISSN)1758-5872</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2012-12"></date><biblScope unit="volume">4</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="241">241</biblScope><biblScope unit="page" to="249">249</biblScope></imprint></monogr><idno type="istex">7B825E43DB430BE8729B3832C34CC2FECE0B7E91</idno><idno type="DOI">10.1111/j.1758-5872.2012.00219.x</idno><idno type="ArticleID">APPY219</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012-07-16</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Brain‐derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD).</p></abstract><abstract><p>One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM‐IV Axis I disorders, and took escitalopram at a daily dose of 5–40 mg. Clinical symptoms were evaluated using the 21‐item Hamilton Depression Rating (HAM‐D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion.</p></abstract><abstract><p>The proportions of M allele carriers were higher in responders than those in non‐responders at 1–8 weeks (P = 0.00001–P = 0.025). The percentile decrease of HAM‐D scores was larger in M allele carriers than those in patients possessing VV genotype at 1–8 weeks (P = 0.0002–0.002). The proportion of M allele carriers was higher in remitters than in non‐remitters at 2–8 weeks (P = 0.003–P = 0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results.</p></abstract><abstract><p>These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>brain‐derived neurotrophic factor</term></item><item><term>escitalopram</term></item><item><term>major depressive disorder</term></item><item><term>single nucleotide polymorphism</term></item><item><term>treatment response</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>ORIGINAL ARTICLE</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-11-16">Received</change><change when="2012-06-07">Registration</change><change when="2012-07-16">Created</change><change when="2012-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/7B825E43DB430BE8729B3832C34CC2FECE0B7E91/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="appy219" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley">10.1111/(ISSN)1758-5872</doi><issn type="print">1758-5864</issn><issn type="electronic">1758-5872</issn><idGroup><id type="product" value="APPY"></id></idGroup><titleGroup><title sort="ASIA-PACIFIC PSYCHIATRY" type="main">Asia‐Pacific Psychiatry</title><title type="short">Asia‐Pacific Psychiatry</title></titleGroup></publicationMeta><publicationMeta level="part" position="12104"><doi>10.1111/appy.2012.4.issue-4</doi><copyright ownership="publisher">© 2012 Wiley Publishing Asia Pty Ltd</copyright><numberingGroup><numbering number="4" type="journalVolume">4</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2012-12">December 2012</coverDate></publicationMeta><publicationMeta level="unit" position="40" status="forIssue" type="article"><doi>10.1111/j.1758-5872.2012.00219.x</doi><idGroup><id type="unit" value="APPY219"></id></idGroup><countGroup><count number="9" type="pageTotal"></count></countGroup><titleGroup><title type="tocHeading1">ORIGINAL ARTICLES</title><title type="articleCategory">ORIGINAL ARTICLE</title></titleGroup><copyright ownership="publisher">Copyright © 2012 Blackwell Publishing Asia Pty Ltd</copyright><eventGroup><event agent="bestset" date="2012-07-16" type="xmlCreated"></event><event date="2011-11-16" type="manuscriptReceived"></event><event date="2012-06-07" type="manuscriptAccepted"></event><event type="publishedOnlineEarlyUnpaginated" date="2012-08-16"></event><event type="firstOnline" date="2012-08-16"></event><event type="publishedOnlineFinalForm" date="2012-12-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-25"></event></eventGroup><numberingGroup><numbering type="pageFirst">241</numbering><numbering type="pageLast">249</numbering></numberingGroup><correspondenceTo><lineatedText><line><b>Correspondence</b></line><line>Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐gu, Seoul 136‐705, Korea.</line><line>Tel: +82 2 920 5354</line><line>Fax: +82 2 923 3507, ext. 5998</line><line>Email: <email>leeminso@korea.ac.kr</email></line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APPY.APPY219.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="short">BDNF <i>V66M</i> and escitalopram in MDD</title><title type="shortAuthors">H.<fc>S</fc>. <fc>C</fc>hang <i>et al</i>.</title><title type="main">Association between brain‐derived neurotrophic factor <i><fc>V</fc>66<fc>M</fc></i> and treatment responses to escitalopram in patients with major depressive disorder</title></titleGroup><creators><creator affiliationRef="#appy219-aff-0001" creatorRole="author" xml:id="appy219-cr-0001"><personName><givenNames>Hun Soo</givenNames><familyName>Chang</familyName><degrees>MD PhD</degrees></personName></creator><creator affiliationRef="#appy219-aff-0001 #appy219-aff-0002" creatorRole="author" xml:id="appy219-cr-0002"><personName><givenNames>Hwa‐Young</givenNames><familyName>Lee</familyName><degrees>MD PhD</degrees></personName></creator><creator affiliationRef="#appy219-aff-0001 #appy219-aff-0002" creatorRole="author" xml:id="appy219-cr-0003"><personName><givenNames>Byung‐Joo</givenNames><familyName>Ham</familyName><degrees>MD PhD</degrees></personName></creator><creator affiliationRef="#appy219-aff-0003" creatorRole="author" xml:id="appy219-cr-0004"><personName><givenNames>Yong Chon</givenNames><familyName>Park</familyName><degrees>MD PhD</degrees></personName></creator><creator affiliationRef="#appy219-aff-0004" creatorRole="author" xml:id="appy219-cr-0005"><personName><givenNames>Sang‐Woo</givenNames><familyName>Hahn</familyName><degrees>MD PhD</degrees></personName></creator><creator affiliationRef="#appy219-aff-0001" creatorRole="author" xml:id="appy219-cr-0006"><personName><givenNames>Yoo‐Jung</givenNames><familyName>Jeong</familyName><degrees>MS</degrees></personName></creator><creator affiliationRef="#appy219-aff-0001" creatorRole="author" xml:id="appy219-cr-0007"><personName><givenNames>Bohye</givenNames><familyName>Kim</familyName><degrees>MS</degrees></personName></creator><creator affiliationRef="#appy219-aff-0001 #appy219-aff-0002" corresponding="yes" creatorRole="author" xml:id="appy219-cr-0008"><personName><givenNames>Min‐Soo</givenNames><familyName>Lee</familyName><degrees>MD PhD</degrees></personName></creator></creators><affiliationGroup><affiliation countryCode="KR" xml:id="appy219-aff-0001"><orgDiv>Pharmacogenomic Research Center for Psychotropic Drugs</orgDiv><orgName>Korea University</orgName><address><city>Seoul</city><country>Korea</country></address></affiliation><affiliation countryCode="KR" xml:id="appy219-aff-0002"><orgDiv>Department of Psychiatry</orgDiv><orgDiv>College of Medicine</orgDiv><orgName>Korea University</orgName><address><city>Seoul</city><country>Korea</country></address></affiliation><affiliation countryCode="KR" xml:id="appy219-aff-0003"><orgDiv>Department of Neuropsychiatry</orgDiv><orgDiv>College of Medicine</orgDiv><orgName>Hanyang University</orgName><address><city>Seoul</city><country>Korea</country></address></affiliation><affiliation countryCode="KR" xml:id="appy219-aff-0004"><orgDiv>Department of Psychiatry</orgDiv><orgDiv>College of Medicine</orgDiv><orgName>Soonchunhyang University</orgName><address><city>Seoul</city><country>Korea</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="appy219-kwd-0001">brain‐derived neurotrophic factor</keyword><keyword xml:id="appy219-kwd-0002">escitalopram</keyword><keyword xml:id="appy219-kwd-0003">major depressive disorder</keyword><keyword xml:id="appy219-kwd-0004">single nucleotide polymorphism</keyword><keyword xml:id="appy219-kwd-0005">treatment response</keyword></keywordGroup><fundingInfo><fundingAgency>Korea Health 21 R&D project</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Ministry of Health and Welfare, Republic of Korea</fundingAgency><fundingNumber>A030001</fundingNumber></fundingInfo><fundingInfo><fundingAgency>H. Lundbeck A/S</fundingAgency></fundingInfo><abstractGroup><abstract type="main"><title type="main">Abstract</title><section xml:id="appy219-sec-0001"><title type="main">Introduction</title><p>Brain‐derived neurotrophic factor (<fc>BDNF</fc>) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the <fc>BDNF</fc> gene, <i><fc>V</fc>66<fc>M</fc></i> (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the <i><fc>V</fc>66<fc>M</fc></i> polymorphism and the response to escitalopram in patients with major depressive disorder (<fc>MDD</fc>).</p></section><section xml:id="appy219-sec-0002"><title type="main">Methods</title><p>One hundred and fifteen <fc>K</fc>orean patients were examined using the <fc>S</fc>tructured <fc>C</fc>linical <fc>I</fc>nterview for <fc>DSM‐IV A</fc>xis <fc>I</fc> disorders, and took escitalopram at a daily dose of 5–40 mg. Clinical symptoms were evaluated using the 21‐item <fc>H</fc>amilton <fc>D</fc>epression <fc>R</fc>ating (<fc>HAM</fc>‐<fc>D</fc>) scale during 12 weeks of treatment. The genotypes were determined using <fc><i>Nla</i>III</fc> digestion.</p></section><section xml:id="appy219-sec-0003"><title type="main">Results</title><p>The proportions of <i><fc>M</fc></i> allele carriers were higher in responders than those in non‐responders at 1–8 weeks (<i><fc>P</fc></i> = 0.00001–<i><fc>P</fc></i> = 0.025). The percentile decrease of <fc>HAM</fc>‐D scores was larger in <i><fc>M</fc></i> allele carriers than those in patients possessing <i><fc>VV</fc></i> genotype at 1–8 weeks (<i><fc>P</fc></i> = 0.0002–0.002). The proportion of <i><fc>M</fc></i> allele carriers was higher in remitters than in non‐remitters at 2–8 weeks (<i><fc>P</fc></i> = 0.003–<i><fc>P</fc></i> = 0.038). The comparison between <fc>VM</fc> heterozygotes and homozygotes (<fc>VV</fc> or <fc>MM</fc>) showed similar results.</p></section><section xml:id="appy219-sec-0004"><title type="main">Discussion</title><p>These results suggest that <i><fc>BDNF V</fc>66<fc>M</fc></i> affects the therapeutic action of escitalopram in <fc>MDD</fc> and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with <fc>MDD</fc>.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>BDNF V66M and escitalopram in MDD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder</title></titleInfo><name type="personal"><namePart type="given">Hun Soo</namePart><namePart type="family">Chang</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hwa‐Young</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Byung‐Joo</namePart><namePart type="family">Ham</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yong Chon</namePart><namePart type="family">Park</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>Department of Neuropsychiatry, College of Medicine, Hanyang University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sang‐Woo</namePart><namePart type="family">Hahn</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoo‐Jung</namePart><namePart type="family">Jeong</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bohye</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Min‐Soo</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐gu, Seoul 136‐705, Korea.Tel: +82 2 920 5354Fax: +82 2 923 3507, ext. 5998Email:</affiliation><affiliation>E-mail: leeminso@korea.ac.kr</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2012-12</dateIssued><dateCreated encoding="w3cdtf">2012-07-16</dateCreated><dateCaptured encoding="w3cdtf">2011-11-16</dateCaptured><dateValid encoding="w3cdtf">2012-06-07</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Brain‐derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD).</abstract><abstract>One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM‐IV Axis I disorders, and took escitalopram at a daily dose of 5–40 mg. Clinical symptoms were evaluated using the 21‐item Hamilton Depression Rating (HAM‐D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion.</abstract><abstract>The proportions of M allele carriers were higher in responders than those in non‐responders at 1–8 weeks (P = 0.00001–P = 0.025). The percentile decrease of HAM‐D scores was larger in M allele carriers than those in patients possessing VV genotype at 1–8 weeks (P = 0.0002–0.002). The proportion of M allele carriers was higher in remitters than in non‐remitters at 2–8 weeks (P = 0.003–P = 0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results.</abstract><abstract>These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.</abstract><note type="funding">Korea Health 21 R&D project</note><note type="funding">Ministry of Health and Welfare, Republic of Korea - No. A030001; </note><note type="funding">H. Lundbeck A/S</note><subject><genre>keywords</genre><topic>brain‐derived neurotrophic factor</topic><topic>escitalopram</topic><topic>major depressive disorder</topic><topic>single nucleotide polymorphism</topic><topic>treatment response</topic></subject><relatedItem type="host"><titleInfo><title>Asia‐Pacific Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>Asia‐Pacific Psychiatry</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>ORIGINAL ARTICLE</topic></subject><identifier type="ISSN">1758-5864</identifier><identifier type="eISSN">1758-5872</identifier><identifier type="DOI">10.1111/(ISSN)1758-5872</identifier><identifier type="PublisherID">APPY</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>241</start><end>249</end><total>9</total></extent></part></relatedItem><identifier type="istex">7B825E43DB430BE8729B3832C34CC2FECE0B7E91</identifier><identifier type="DOI">10.1111/j.1758-5872.2012.00219.x</identifier><identifier type="ArticleID">APPY219</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2012 Wiley Publishing Asia Pty LtdCopyright © 2012 Blackwell Publishing Asia Pty Ltd</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001053 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001053 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:7B825E43DB430BE8729B3832C34CC2FECE0B7E91
|texte= Association between brain‐derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder
}}
| This area was generated with Dilib version V0.6.31. |  |